Bruton�s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor\n(BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies.\nTargeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib\nis the first-in-class agent. A few other BTK inhibitors (BTKi) are also under development (e.g.,\nacalabrutinib). While the predominant action of BTKi is the blockade of B-cell receptor pathway\nwithin malignant B-cells, increasing the knowledge of off-target effects as well as a potential\nrole for B-cells in proliferation of solid malignancies is expanding the indication of BTKi into\nnon-hematological malignancies. In addition to the expansion of the role of BTKi monotherapy,\ncombination therapy strategies utilizing ibrutinib with established regimens and combination with\nmodern immunotherapy compounds are being explored.
Loading....